TSHA - Company ID 0001806310
The table below shows Taysha Gene Therapies, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$40.88M | -$22.02M | -$19.80M | -$20.18M | -$40.94M | -$22.04M |
| Capital expenditure | $24.00K | $378.00K | $140.00K | $3.90M | $8.43M | $534.00K |
| Investing cash flow | -$3.02M | -$371.00K | -$140.00K | -$3.90M | -$11.43M | -$534.00K |
| Dividends paid | - | - |
Taysha Gene Therapies, Inc. reported operating cash flow of -$93.09M for fiscal year 2025. That is down 14.6% from -$81.22M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$30.73M (FY 2020) to -$93.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $711.00K | -$52.00K | -$22.00K | -$370.00K | -$107.00K | - |